These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 20207522

  • 1. Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections.
    Ohsaki Y, Morita K, Takeda H, Kishino S, Okumura S, Fujiuchi S.
    Int J Antimicrob Agents; 2010 Jun; 35(6):603-5. PubMed ID: 20207522
    [Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 3. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G, Gajjar D, Swan S, Marbury T, Grasela DM, Wang Z.
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [Abstract] [Full Text] [Related]

  • 4. Concentrations of the des-F(6)-quinolone garenoxacin in plasma and joint cartilage of immature rats.
    Kastner M, Rahm U, Baumann-Wilschke I, Bello A, Stahlmann R.
    Arch Toxicol; 2004 Feb; 78(2):61-7. PubMed ID: 14661070
    [Abstract] [Full Text] [Related]

  • 5. Clinical studies of garenoxacin.
    Takagi H, Tanaka K, Tsuda H, Kobayashi H.
    Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608
    [Abstract] [Full Text] [Related]

  • 6. Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.
    Krishna G, Kisicki JC, Olsen S, Grasela DM, Wang Z.
    Pharmacotherapy; 2007 Jul; 27(7):963-9. PubMed ID: 17594201
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection.
    Ito F, Ohno Y, Toyoshi S, Kaito D, Koumei Y, Endo J, Kamamiya F, Mori H, Mori M, Morishita M, Funaguchi N, Minatoguchi S.
    Ther Adv Respir Dis; 2016 Feb; 10(1):34-42. PubMed ID: 26660898
    [Abstract] [Full Text] [Related]

  • 8. Garenoxacin pharmacokinetics in patients undergoing maintenance hemodialysis.
    Aoyama T, Kamata K, Kishino S.
    Hemodial Int; 2017 Apr; 21(2):206-212. PubMed ID: 27549744
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
    Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Dalhoff A, Naber KG.
    Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
    [Abstract] [Full Text] [Related]

  • 10. Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.
    Tanigawara Y, Nozawa K, Tsuda H.
    Eur J Clin Pharmacol; 2012 Jan; 68(1):39-53. PubMed ID: 21796376
    [Abstract] [Full Text] [Related]

  • 11. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z, Grasela DM, Krishna G.
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [Abstract] [Full Text] [Related]

  • 12. The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers.
    Krishna G, Kisicki JC, Olsen S, Grasela DM, Wang Z.
    J Clin Pharmacol; 2007 May; 47(5):628-32. PubMed ID: 17395892
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of pradofloxacin and doxycycline in serum, saliva, and tear fluid of cats after oral administration.
    Hartmann A, Krebber R, Daube G, Hartmann K.
    J Vet Pharmacol Ther; 2008 Apr; 31(2):87-94. PubMed ID: 18307499
    [Abstract] [Full Text] [Related]

  • 14. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
    van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR.
    J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
    [Abstract] [Full Text] [Related]

  • 15. Once-daily gentamicin dosing in children with febrile neutropenia resulting from antineoplastic therapy.
    Inparajah M, Wong C, Sibbald C, Boodhan S, Atenafu EG, Naqvi A, Dupuis LL.
    Pharmacotherapy; 2010 Jan; 30(1):43-51. PubMed ID: 20030472
    [Abstract] [Full Text] [Related]

  • 16. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 17. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD.
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [Abstract] [Full Text] [Related]

  • 18. [Prediction on the efficacy of fluoroquinolones for anaerobic infections using Monte Carlo simulation].
    Mikamo H, Tanaka K, Watanabe K.
    Jpn J Antibiot; 2007 Dec; 60(6):335-43. PubMed ID: 18447205
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic behaviour of enrofloxacin in greater rheas following a single-dose intramuscular administration.
    de Lucas JJ, Navarro JL, Rubio S, Vignolo PE, Asis VC, González F, Rodríguez C.
    Vet J; 2008 Jan; 175(1):136-8. PubMed ID: 17303451
    [Abstract] [Full Text] [Related]

  • 20. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
    Conte JE, Golden JA, McIver M, Zurlinden E.
    Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.